Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load

被引：0
|
作者：
Chen, S. [1 ]
Lai, H. [2 ]
Tsou, H. [3 ]
Shao, Y. [4 ]
Chang, C. [5 ]
Su, T. [4 ]
Liu, T. [3 ]
Chen, L. [6 ]
Cheng, A. [4 ]
Hsu, C. [4 ]
机构：
[1] Taipei Vet Gen Hosp, Taipei, Taiwan
[2] China Med Univ Hosp, Taichung, Taiwan
[3] Natl Hlth Res Inst, Miaoli, Taiwan
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] MacKay Mem Hosp, Taipei, Taiwan
[6] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-126
引用
收藏
页码：S141 / S142
页数：2
相关论文
共 50 条
  • [1] Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: focusing on hepatic safety and viral kinetics
    Chen, San-Chi
    Tsou, Hsiao-Hui Sophie
    Lee, Teng-Yu
    Wang, Hung-Wei
    Chen, Yen-Hao
    Wang, Tseng-En
    Su, Yung-Yeh
    Yang, Shengshun
    Chiu, Chang-Fang
    Liu, Tsang-Wu
    Cheng, Ann-Lii
    Chen, Li-Tzong
    Hsu, Chiun
    JOURNAL OF HEPATOLOGY, 2023, 78 : S588 - S589
  • [2] High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection
    Ohata, K
    Hamasaki, K
    Toriyama, K
    Ishikawa, H
    Nakao, K
    Eguchi, K
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (06) : 670 - 675
  • [3] Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients
    Kim, Hyeyeong
    Cheon, Jaekyung
    Ha, Yeongjung
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kim, Chan
    Jung, Sang-Hoon
    Chon, Hong Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Kim, Hyeyeong
    Kim, Han Sang
    Kim, Chang Gon
    Kim, Ilhwan
    Kang, Beodeul
    Kim, Chan
    Jung, Sanghoon
    Ha, Yeonjung
    Chon, Hong Jae
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [6] Result of atezolizumab plus bevacizumab for advanced or metastatic hepatocellular carcinoma in Vietnamese patients
    Hoang, H. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S88 - S88
  • [7] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Yoo, Changhoon
    Hong, Jung Yong
    Kim, Han Sang
    Lee, Dae-Won
    Lee, Myung Ah
    Kim, Jin Won
    Kim, Ilhwan
    Oh, Sang-Bo
    Hwang, Jun-Eul
    Chon, Hong Jae
    Lim, Ho Yeong
    LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
  • [8] PREDICTING RESPONSE TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA
    Cappuyns, Sarah
    Pique-Gili, Marta
    Esteban-Fabro, Roger
    Philips, Gino
    Pinyol, Roser
    Vandecaveye, Vincent
    Abril-Fornaguera, Jordi
    Haber, Philipp
    Verslype, Chris
    Van Cutsem, Eric
    Lambrechts, Diether
    Villanueva, Augusto
    Dekervel, Jeroen
    Llovet, Josep M.
    HEPATOLOGY, 2023, 78 : S1871 - S1872
  • [9] Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab
    Hsu, Chiun
    Ducreux, Michel
    Zhu, Andrew X.
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Galle, Peter R.
    Finn, Richard S.
    Chen, Ethan
    Ma, Ning
    Hu, Youyou
    Li, Lindong
    Cheng, Ann-Lii
    LIVER CANCER, 2023, 12 (01) : 44 - 56
  • [10] Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
    Itoh, Shinji
    Ikeda, Masafumi
    HEPATOBILIARY SURGERY AND NUTRITION, 2022,
12345